McKinnon J G, Hoover S K, Inge T H, Bear H D
Department of Surgery, Massey Cancer Center, Medical College of Virginia, Richmond.
Cancer Immunol Immunother. 1990;32(1):38-44. doi: 10.1007/BF01741722.
Large numbers of cytotoxic T lymphocytes (CTL) could be generated from tumor-draining lymph nodes (DLN) from mice bearing PHS-5 tumor by culturing at low density with autologous tumor cell stimulators and 20 U/ml recombinant interleukin-2 (IL-2). Outgrowth of metastatic tumor cells in culture was prevented by use of this hypoxanthine/aminopterin/thymidine-sensitive mutant of P815, PHS-5. After 9 days in culture, lymphoid cells demonstrated specific cytotoxicity against autologous tumor target cells. Lymph node cells could be expanded continuously in culture with repeated tumor stimulation with up to 7500-fold increase in cell number by 6 weeks; although CTL could be activated from tumor-bearing host spleen cells in short-term culture, they showed no significant growth in long-term cultures. Phenotypically, DLN cells were a mixture of CD8+ and CD4+ cells immediately after harvest but after 2 weeks in culture they were predominantly CD8+ CD4-. CTL could be generated from tumor-bearing mice 10-14 days after i.d. tumor inoculation into the abdominal wall, but the immune response declined both in spleen and DLN by 21 days. Much greater CTL activity could be generated from axillary DLN that contained metastases than from non-draining popliteal nodes that were free of metastatic tumor cells. Some CTL activity could be generated from DLN with the addition of IL-2 alone but was further increased by the addition of more tumor cells as stimulators. When adoptively transferred to a host with 3-day P815 liver metastases, lymphocytes from DLN activated in vitro were able to reduce or eliminate metastases with very little or no IL-2 administered concomitantly. As few as 10(6) cells were therapeutically effective, and in vivo efficacy was tumor-specific, since L5178Y liver metastases were not affected.
通过与自体肿瘤细胞刺激物和20 U/ml重组白细胞介素-2(IL-2)以低密度培养,可从携带PHS-5肿瘤的小鼠的肿瘤引流淋巴结(DLN)中产生大量细胞毒性T淋巴细胞(CTL)。使用这种P815的次黄嘌呤/氨基蝶呤/胸腺嘧啶核苷敏感突变体PHS-5可防止培养物中转移性肿瘤细胞的生长。培养9天后,淋巴细胞表现出对自体肿瘤靶细胞的特异性细胞毒性。通过重复肿瘤刺激,淋巴结细胞可在培养中持续扩增,到6周时细胞数量增加多达7500倍;尽管CTL可在短期培养中从荷瘤宿主脾细胞中激活,但它们在长期培养中无显著生长。从表型上看,DLN细胞在收获后立即是CD8 +和CD4 +细胞的混合物,但培养2周后它们主要是CD8 + CD4 -。在腹壁皮下接种肿瘤后10 - 14天可从荷瘤小鼠中产生CTL,但到21天时脾脏和DLN中的免疫反应均下降。与不含转移性肿瘤细胞的非引流腘窝淋巴结相比,含有转移灶的腋窝DLN可产生更强的CTL活性。单独添加IL-2可从DLN中产生一些CTL活性,但添加更多肿瘤细胞作为刺激物可进一步增强。当将体外激活的DLN淋巴细胞过继转移到患有3天P815肝转移的宿主时,能够减少或消除转移灶,同时给予很少或不给予IL-2。低至10^6个细胞就具有治疗效果,并且体内疗效具有肿瘤特异性,因为L5178Y肝转移不受影响。